Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 25;21(3):788.
doi: 10.3390/s21030788.

Deciphering the Disaggregation Mechanism of Amyloid Beta Aggregate by 4-(2-Hydroxyethyl)-1-Piperazinepropanesulfonic Acid Using Electrochemical Impedance Spectroscopy

Affiliations

Deciphering the Disaggregation Mechanism of Amyloid Beta Aggregate by 4-(2-Hydroxyethyl)-1-Piperazinepropanesulfonic Acid Using Electrochemical Impedance Spectroscopy

Hien T Ngoc Le et al. Sensors (Basel). .

Abstract

Aggregation of amyloid-β (aβ) peptides into toxic oligomers, fibrils, and plaques is central in the molecular pathogenesis of Alzheimer's disease (AD) and is the primary focus of AD diagnostics. Disaggregation or elimination of toxic aβ aggregates in patients is important for delaying the progression of neurodegenerative disorders in AD. Recently, 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS) was introduced as a chemical agent that binds with toxic aβ aggregates and transforms them into monomers to reduce the negative effects of aβ aggregates in the brain. However, the mechanism of aβ disaggregation by EPPS has not yet been completely clarified. In this study, an electrochemical impedimetric immunosensor for aβ diagnostics was developed by immobilizing a specific anti-amyloid-β (aβ) antibody onto a self-assembled monolayer functionalized with a new interdigitated chain-shaped electrode (anti-aβ/SAM/ICE). To investigate the ability of EPPS in recognizing AD by extricating aβ aggregation, commercially available aβ aggregates (aβagg) were used. Electrochemical impedance spectroscopy was used to probe the changes in charge transfer resistance (Rct) of the immunosensor after the specific binding of biosensor with aβagg. The subsequent incubation of the aβagg complex with a specific concentration of EPPS at different time intervals divulged AD progression. The decline in the Rct of the immunosensor started at 10 min of EPPS incubation and continued to decrease gradually from 20 min, indicating that the accumulation of aβagg on the surface of the anti-aβ/SAM/ICE sensor has been extricated. Here, the kinetic disaggregation rate k value of aβagg was found to be 0.038. This innovative study using electrochemical measurement to investigate the mechanism of aβagg disaggregation by EPPS could provide a new perspective in monitoring the disaggregation periods of aβagg from oligomeric to monomeric form, and then support for the prediction and handling AD symptoms at different stages after treatment by a drug, EPPS.

Keywords: 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid; Alzheimer’s disease; amyloid beta aggregate; electrochemical impedance spectroscopy; impedimetric immunosensor; kinetic disaggregation of protein.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(a) Fabrication of ICE, (b) Photograph of ICE, and (c) Scanning electron microscope image of chain-shaped gold finger of ICE.
Figure 2
Figure 2
(ae) Development procedure the immunosensor anti-aβ/SAM/ICE for the recognition aβagg, (f) impedimetric measurement mechanism in the recognition aβagg by the developed biosensor anti-aβ/SAM/ICE, and (g) impedimetric results represent by Nyquist plot at each step of the development anti-aβ/SAM/ICE biosensor in the recognition aβagg.
Figure 3
Figure 3
EIS results at each step of the development of biosensor anti-aβ/SAM/ICE display in (a) Nyquist plots and (b) charge-transfer resistance (Rct).
Figure 4
Figure 4
FT-IR results for the fabrication of the anti-aβ/SAM/ICE biosensor.
Figure 5
Figure 5
EIS results of the biosensor anti-aβ/SAM/ICE with the treatment in EPPS at different time intervals display in (a) Nyquist plots and (b) Normalization of Rct. (n = 3; three data points shown).
Figure 6
Figure 6
Gel electrophoresis results of aβpep and aβagg.
Figure 7
Figure 7
EIS results monitoring the disaggregation aβagg with the treatment in EPPS at different time intervals display in (a) Nyquist plots and (b) Normalization of Rct. (n = 3; three data points shown).
Figure 8
Figure 8
(a) Disaggregation mechanism of aβagg by EPPS, and (b) the impact of EPPS on aβpep.
Figure 9
Figure 9
EIS results monitoring the impact of EPPS on the aβpep at different time intervals display in (a) Nyquist plots and (b) Normalization of Rct. (n = 3; three data points shown).
Figure 10
Figure 10
Fitting of two sets of disaggregation data for aβagg and aβpep, respectively; symbols and bars represent the average and standard deviation of the data (n = 3).

Similar articles

Cited by

References

    1. Murphy M.P., LeVine H., III Alzheimer’s Disease and the β-Amyloid Peptide. J. Alzheimer’s Dis. 2010;19:311. doi: 10.3233/JAD-2010-1221. - DOI - PMC - PubMed
    1. Blennow K., Mattsson N., Schöll M., Hansson O., Zetterberg H. Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol. Sci. 2015;36:297–309. doi: 10.1016/j.tips.2015.03.002. - DOI - PubMed
    1. Clifford R.J., Jr., Bennett D.A., Blennow K., Carrillod M.C., Dunne B., Haeberleinf S.B., Holtzmang D.M., Jagusth W., Jesseni F., Karlawishj J., et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14:535–562. - PMC - PubMed
    1. O’Brien R.J., Wong P.C. Amyloid Precursor Protein Processing and Alzheimer’s Disease. Annu. Rev. Neurosci. 2011;34:185–204. doi: 10.1146/annurev-neuro-061010-113613. - DOI - PMC - PubMed
    1. Yagi H., Ozawa D., Sakurai K., Kawakami T., Kuyama H., Nishimura O., Shimanouchi T., Kuboi R., Naiki H., Goto Y. Laser-induced Propagation and Destruction of Amyloid β Fibrils. J. Biol. Chem. 2010;285:19660–19667. doi: 10.1074/jbc.M109.076505. - DOI - PMC - PubMed

Substances

LinkOut - more resources